Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings

OBJECTIVE: Maraviroc, a chemokine co-receptor type 5 (CCR5) antagonist, has demonstrated comparable efficacy and safety to efavirenz, each in combination with zidovudine/lamivudine, over 96 weeks in the Maraviroc vs. Efavirenz Regimens as Initial Therapy (MERIT) study. Here we report 5-year findings...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Cooper, David A., Heera, Jayvant, Ive, Prudence, Botes, Mariette, Dejesus, Edwin, Burnside, Robert, Clumeck, Nathan, Walmsley, Sharon, Lazzarin, Adriano, Mukwaya, Geoffrey, Saag, Michael, van Der Ryst, Elna
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2014
Matèries:
Clinical Science
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3940293/
https://ncbi.nlm.nih.gov/pubmed/24983542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAD.0000000000000131
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars